Acute Myeloid Leukemia
Conditions
Keywords
AML, Secondary AML, Leukemia
Brief summary
This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.
Detailed description
This is a two-stage, open-label, phase 2, multicenter study of amonafide L-malate in combination with standard-dose cytarabine in subjects with secondary AML. Amonafide is a DNA intercalating agent and inhibitor of topoisomerase II that has been extensively studied in patients with malignant solid tumors. Amonafide has also been studied in patients with AML. In three phase I clinical trials, amonafide demonstrated anti-leukemic activity, both as monotherapy and in combination with cytarabine. This protocol is designed to further assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML. The duration of the study is approximately 42 months: enrollment approximately 18 months and subject duration up to 24 months
Interventions
DRUGAmonafide L-Malate
DRUGCytarabine
Sponsors
Xanthus Pharmaceuticals, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologic diagnosis of AML (≥20% blasts of myeloid lineage in bone marrow), with FAB classification other than M3, secondary to either: 1. Known and documented exposure to prior leukemogenic chemotherapy or radiotherapy, OR 2. Diagnosis of MDS for ≥3 months prior to study entry (prior BM slides documenting MDS must be available for central pathology review). * Age 18 years or older. * ECOG performance status ≤2. * No prior induction chemotherapy for AML; at least 4 weeks since completion of prior chemotherapy for MDS. (Subjects with rapidly rising blast count may be enrolled within 4 weeks of prior cytotoxic chemotherapy). * Fertile and sexually active men and women must use effective contraception throughout study. Women of childbearing potential must have a negative pregnancy test. * LVEF ≥50% by MUGA or ECHO. * Adequate renal function: serum creatinine ≤1.5 x ULN. * Adequate hepatic function: total serum bilirubin ≤1.5 x ULN as well as serum AST and ALT ≤1.5 x ULN. * Subject must be able to participate fully in all aspects of the trial. * Subject must give voluntary, written consent and HIPAA authorization (US only).
Exclusion criteria
* Histologic diagnosis of FAB M3 AML (acute promyelocytic leukemia). * Clinically active CNS leukemia. * Known to be HIV positive. * Prior induction chemotherapy for AML. * Known active hepatitis B or C or other active liver disease. * Any major surgery or radiation therapy within 4 weeks prior to study entry. * Prior cytotoxic chemotherapy within 4 weeks prior to study entry.(Subjects with rapidly rising blast count may be enrolled within 4 weeks of prior cytotoxic chemotherapy). * Persistent chronic non-hematologic toxicity from prior chemotherapy (other than alopecia) that is \> than grade 1. * Serious concomitant illness (e.g., active pulmonary infection, unstable angina or myocardial infarction within 3 months of study entry, congestive heart failure ≥AHA class 2, stroke within 3 months prior to study entry, uncontrolled hypertension, uncontrolled diabetes, actively bleeding gastric ulcer, etc.). * Women who are pregnant or lactating. * History of clinically significant allergic reactions attributed to compounds similar to amonafide or cytarabine. * Prior enrollment on this trial. * Any other known condition (familial, sociological, or geographic) or behavior (including substance abuse, psychological or psychiatric illness), which in the investigator's opinion would make the subject a poor candidate for this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - To determine the rate of complete remission with or without complete hematopoietic recovery (CR + CRi). | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlate PK exposure of amonafide and acetylation of amonafide with safety and efficacy assessments in individual subjects | — |
| Determine the median duration of complete remission with or without complete hematopoietic recovery (CR or CRi) | — |
| Determine the proportion of subjects remaining in complete remission (CR +CRi) at 6 months, at 12 months and at 18 months | — |
| Define the safety profile and confirm the acceptability of amonafide and cytarabine | — |
| Correlate clinical responses and duration of responses with specific cytogenetic abnormalities | — |
| Define the population pharmacokinetic (PK) profile of amonafide and its metabolites when administered as an intravenous infusion daily x 5 days in combination with a standard-dose of cytarabine | — |
| Determine the median duration of overall survival (OS) | — |
Countries
Canada, United States
Outcome results
None listed